Product Description
LY01620 leverages mRNA to express the HPV-specific antigens E6 and E7, thereby eliciting a robust antigen-specific T-cell response capable of eradicating the HPV-infected cervical epithelial cells. This immunotherapeutic approach is designed to block cervical carcinogenesis and restore epithelial homeostasis. Preclinical investigations have consistently demonstrated LY01620's potent immunogenicity in eliciting antigen-specific T-cell responses across diverse animal models. Furthermore, LY01620 also exhibits significant antitumor efficacy underpinned by its mechanism of action in tumor-bearing mouse models without inducing appreciable toxicity upon repeated administration, underscoring its promising efficacy and safety profiles. (Sourced from: https://www.publicnow.com/view/8CB2A1680F0D1C322DF4D765AAB9583D3B15CF18?1723542502)
Mechanisms of Action: Vaccine
Novel Mechanism: No
Modality: Vaccine
Route of Administration: Intramuscular
FDA Designation: None *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: Nanjing Jimai Biotechnology Co., Ltd.
Company Location:
Company CEO:
Additonal Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Highest Development Phases
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
|---|